AY 9944;SMDC ID 874805;AY-9944;AY9944;N.N'-Di-<2-chlor-benzyl>-cyclohexan-trans-1.4-bis-methylamin;trans-1,4-Bis-(2-chlor-benzylaminomethyl)-cyclohexan
Provided are assays useful for detecting and monitoring autophagy and phospholipidosis, including the progression of lysosomal storage diseases. Drugs and treatments for lysosomal storage diseases can be monitored for effectiveness in lysosomal storage disease conditions. Drug candidates and suspected toxic agents can also be screened for toxicity to cells, tissues and organs. Also provided are methods for distinguishing between phospholipidosis activators and autophagy pathway perturbation agents.
Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
UTILISATION DE DIAMINES ALICYCLIQUES COMME IMMUNOMODULATEURS
申请人:NEOVACS
公开号:EP0841909B1
公开(公告)日:2002-03-13
ANTIMICROBIAL AGENTS
申请人:Ranbaxy Laboratories Limited
公开号:EP1879877B1
公开(公告)日:2013-01-02
Compositions and methods for treatment of viral diseases
申请人:Johansen Lisa M.
公开号:US20100092479A1
公开(公告)日:2010-04-15
The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).